GCI Health To Promote Botox for Migraines
Allergan has selected GCI Health to support the launch of Botox for use in the preventive treatment of chronic migraine in adults.
Botox was approved by the FDA on October 15 for use in preventing migraines in patients who suffer from headaches that last four or more hours during 15 or more days in a month. According to the press release announcing the relationship, this is the “sixth therapeutic indication for the product” since 1989.
“Botox, with current annual sales of $1.4
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in